Cellusion Receives U.S. FDA Orphan Drug Designation for CLS001 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Cellusion raises 2.83 Billion Yen (21 Million USD) in Series C Round streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cellusion and Minaris Regenerative Medicine, a member of Showa Denko Materials, Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Celregen Obtains the Exclusive Rights to Develop, Manufacturing and Commercialize CLS001 in Greater China Region; Cellusion Retains Other Regional Rights.The Deal is Worth up to over $100 Million, including Upfront, Development and Sales Milestone Payments, and Tiered Royalties.TOKYO & HANGZHOU, China & SHANGHAI (B.
Cellusion and Celregen, a member of Fosun Pharma, Enter into Exclusive License Agreement of CLS001 for a Corneal Endothelial Cell Regenerative Therapy in the Greater China Region - read this article along with other careers information, tips and advice on BioSpace